Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Poulsen, Mikael K ^a   Nybo, Mads ^a   Dahl, Jordi ^a   Hosbond, Susanne ^a   Poulsen, Tina S ^a   Johansen, Allan ^a   Høilund Carlsen, Poul F ^a   Beck Nielsen, Henning ^a   Rasmussen, Lars M ^a   Henriksen, Jan E ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OSTEOPROTEGERIN; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ARTICLE; B SCAN; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MYOCARDIAL PERFUSION IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; SCREENING TEST; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; CAROTID ARTERY; ECHOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SCINTIGRAPHY; SCINTISCANNING; STATISTICAL MODEL;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAROTID ARTERIES; CAROTID ARTERY DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OSTEOPROTEGERIN; PERFUSION IMAGING; PERIPHERAL ARTERIAL DISEASE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80051591246     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-76     Document Type: Article

References (35)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038. 10.1001/jama.241.19.2035, 430798.
3. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002, 25:894-899. 10.2337/diacare.25.5.894, 11978687.
4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581. 10.1001/jama.287.19.2570, 12020339.
5. Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994, 25:951-957. 10.1161/01.STR.25.5.951, 8165689.
6. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007, 30:2934-2939. 10.2337/dc07-0992, 17712025.
7. Norman PE, Davis WA, Bruce DG, Davis TM. Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2006, 29:575-580. 10.2337/diacare.29.03.06.dc05-1567, 16505509.
8. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009, 301:1547-1555. 10.1001/jama.2009.476, 2895332, 19366774.
9. Rasmussen LM, Ledet T. Osteoprotegerin and diabetic macroangiopathy. Horm Metab Res 2005, 37(Suppl1):90-94.
10. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005, 48:561-568. 10.1007/s00125-004-1652-8, 15700136.
11. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268. 10.1101/gad.12.9.1260, 316769, 9573043.
12. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3, 9108485.
13. Helske S, Kovanen PT, Lindstedt KA, et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 2007, 9:357-363. 10.1016/j.ejheart.2006.10.015, 17254844.
14. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976. 10.1016/j.jacc.2004.06.076, 15542278.
15. Poulsen MK, Henriksen JE, Dahl J, et al. Myocardial ischemia, carotid, and peripheral arterial disease and their interrelationship in type 2 diabetes patients. J Nucl Cardiol 2009, 16:878-887. 10.1007/s12350-009-9118-5, 19685102.
16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S, 9686693.
17. Li R, Duncan BB, Metcalf PA, et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 1994, 25:2377-2383. 10.1161/01.STR.25.12.2377, 7974576.
18. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000, 151:478-487.
19. Gundersen J. Segmental measurements of systolic blood pressure in the extremities including the thumb and the great toe. Acta Chir Scand Suppl 1972, 426:1-90.
20. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003, 108:1404-1418. 10.1161/01.CIR.0000080946.42225.4D, 12975245.
21. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86:631-637. 10.1210/jc.86.2.631, 11158021.
22. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180. 10.1161/01.CIR.0000127957.43874.BB, 15117849.
23. Chung AW, Booth AD, Rose C, Thompson CR, Levin A, van BC. Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction. J Vasc Res 2008, 45:357-362. 10.1159/000119755, 18332634.
24. Ishiyama M, Suzuki E, Katsuda J, et al. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract 2009, 85:189-196. 10.1016/j.diabres.2009.04.023, 19497632.
25. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004, 35:1636-1641. 10.1161/01.STR.0000129790.00318.a3, 15143295.
26. Lundby-Christensen L, Almdal TP, Carstensen B, Tarnow L, Wiinberg N. Carotid intima-media thickness in individuals with and without type 2 diabetes: a reproducibility study. Cardiovasc Diabetol 2010, 9:40. 10.1186/1475-2840-9-40, 2931499, 20727128.
27. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005, 182:175-180. 10.1016/j.atherosclerosis.2005.01.042, 16115489.
28. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008, 159:603-608. 10.1530/EJE-08-0554, 18697793.
29. Prior JO, Quinones MJ, Hernandez-Pampaloni M, et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005, 111:2291-2298. 10.1161/01.CIR.0000164232.62768.51, 15851590.
30. Altinova AE, Toruner F, Akturk M, et al. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. Scand J Clin Lab Invest 2011,
31. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470, 18784090.
32. Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de ZD. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 2006, 15:631-636. 10.1097/01.mnh.0000247496.54882.3f, 17053479.
33. Schoppet M, Al-Fakhri N, Franke FE, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004, 89:4104-4112. 10.1210/jc.2003-031432, 15292354.
34. Ovchinnikova O, Gylfe A, Bailey L, et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice--brief report. Arterioscler Thromb Vasc Biol 2009, 29:1478-1480. 10.1161/ATVBAHA.109.188185, 19592469.
35. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000, 275:20959-20962. 10.1074/jbc.C000290200, 10811631.